Seeking men and women who have Myelofibrosis bone marrow cancer and are not going to have a stem cell transplant for a study of an investigational drug reduce spleen volume and improve symptoms of Myelofibrosis.
Participants in this study will be given either the investigational drug tablet alone or in combination with either Ruxolitinib or Fedratinib tablets. Investigational treatment will be provided in 21 to 28-day cycles over a period of up to 2 years followed by quarterly safety-followup visits for 2 years.
What we're hoping for
We are studying the safety and best dose of an investigational drug given either alone or in combination with other drugs to reduce spleen volume and improve symptoms of Myelofibrosis.
ClinicalTrials.gov Identifier: NCT04817007